![]() |
|
|
Vol. 288, Issue 1, 57-64, January 1999
Drug Delivery System Institute, Ltd., Noda-shi, Chiba, Japan (K.S.,
H.S., S.O.); and
Faculty of Pharmaceutical Science, University of
Tokyo, Hongou, Bunkyo-ku, Tokyo, Japan (Y.S.)
A specific sugar-modified peptide has previously been shown to have
renal targeting potential in vivo and to have a specific binding site
which has been identified in the kidney membrane fraction. In
this report, we studied the inhibitory effects of glycosylated
derivatives on the binding of [3H]Glc-O-C8-AVP [a
glucosylated derivative of Arg8-vasopressin (AVP),
Kd = 55 nM] to clarify the structural
requirements necessary for renal recognition. Glc-S-C7-Me (octyl
-D-thioglucoside) markedly inhibited the binding, to a
much greater extent than Glc-O-C7-Me (octyl
-D-glucoside) and Gal-S-C7-Me (octyl
-D-thiogalactoside). Also, [3H]Glc-S-C7-Me
was shown to have a specific binding site on the kidney membrane
(Kd = 17 nM, Bmax = 24 pmol/mg protein) rather than the liver membrane and, in addition,
Glc-S-C7-Me exhibited effective and selective renal uptake in vivo. To
examine the possibility that Glc-S-C7-Me might be of practical use as a
renal targeting vector, AVP, tryptamine and
4-nitrobenz-2-oxa-1,3-diazole were modified with Glc-S-C8- and
the tissue uptake of the resulting derivatives was evaluated. All of
these derivatives showed clear renal targeting potential because the
apparent uptake clearance by the kidney was greater than 3 ml/min/g
kidney in each case. As far as the AVP derivatives were concerned,
derivatives having different numbers of methylene groups were compared
with Glc-S-C8-AVP. Glc-S-C11-AVP exhibited increased kidney targeting
potential, whereas that of Glc-S-C5-AVP was reduced. These differences
suggest that the "alkylglycoside" moiety is important for renal
uptake. In addition, these renally targeted derivatives inhibited the binding of [3H]Glc-S-C7-Me to the kidney membrane
fraction. Our findings allow us to conclude that the
alkylglycoside is a suitable candidate vector for renal targeting.
This article has been cited by other articles:
![]() |
N. O. Elmagbari, R. D. Egleton, M. M. Palian, J. J. Lowery, W. R. Schmid, P. Davis, E. Navratilova, M. Dhanasekaran, C. M. Keyari, H. I. Yamamura, et al. Antinociceptive Structure-Activity Studies with Enkephalin-Based Opioid Glycopeptides J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 290 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shirota, Y. Kato, K. Suzuki, and Y. Sugiyama Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 459 - 467. [Abstract] [Full Text] [PDF] |
||||